ASPirin in reducing Events in the Elderly: an RCT of low dose aspirin

https://neurodegenerationresearch.eu/survey/aspirin-in-reducing-events-in-the-elderly-an-rct-of-low-dose-aspirin/

Title of study

ASPirin in reducing Events in the Elderly: an RCT of low dose aspirin

Acronym for cohort

ASPREE

Name of Principal Investigator - Title

Prof

Name of Principal Investigator - First name

John

Name of Principal Investigator - Last name

McNeil

Address of institution -Institution

Monash University

Address of institution - Street address

99 Commercial Road

Address of institution - City

Melbourne

Address of institution - Postcode

3004

Country

Australia

Website

https://www.aspree.org/

Contact email

robyn.woods@monash.edu

Funding source

NIH

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Alzheimer's disease and other dementias|Parkinson's disease

Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)

To determine whether regular low dose aspirin extends survival free of dementia and persistent physical disability

Q2b. What distinguishes this case-control study from other studies?

This is not a case control study but an RCT over an average of 5 years of treatment

Q3a. i) Number of publications that involve use of your cohort to date

5

Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)

John McNeil, Monash University, Methods and rationale paper for ASPREE|John McNeil, Monash University, Methods and rationale paper for ASPREE|Elsdon Storey, Monash University, Methods and rationale paper for sub-study on neurocognitive function and neuroimaging (ENVISION)

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available
Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study

The RCT will determine the primary prevention benefits of low dose aspirin in elderly people

Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

70

Q4a. Study criteria: what is the age range of participants at recruitment? To:

until death

Q4b. Study criteria: what are the inclusion criteria?

Able to give informed consent and attend a general practice; aged 70+; either gender; generally

'healthy'

Q4c. Study criteria: what are the exclusion criteria?

History of CVD, dementia, loss of independence, anaemia, very high blood pressure, bleeding risk

Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?

More than 15,000

Q5b. What is the expected number of control participants?

Above 5,000

Q6a. Please describe what measures are used to characterise participants

Neurocognitive assessments, physical and clinical criteria

Q6b. Are there additional measures for participants with the clinical disorder?

No clinical disorder

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

Yes

If YES please specify

death, dementia, persistent physical disability, CVD, stroke, cancer, depression, clinically significant bleeding

Q7. What is the study design?

Randomized Controlled Trial

**Q8. Are your cases matched by
Q9a. Does your study includes a specialised subset of control participants?**

No

**Q9b. If your study includes a specialised subset of control participants please describe
Q10a. Is data collection for this study**

Data collection ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Yes - intend to apply for funding

Q11. Are data collected

Only through the study|Through links to medical records|Through links to other records or registers(Cancer and other registries)

Q12. Is there a system in place to enable re-contact with patients for future studies?

Yes (participants have given permission to be re-contacted via the PIs)

Q13a. Please give information on data stored in a database (1)

Data summarised in database

% Available
Q13a. Please give information on data stored in a database (2)

Database is web-based

% Available
Q13a. Please give information on data stored in a database (3)

No

% Available
Q13a. Please give information on data stored in a database (4)

No

% Available
Q13a. Please give information on data stored in a database (5)

No

% Available
Please specify language used
% Available
Q13b. Please give information on how data is held as individual records

No

% Available
Q14a. Are data available to other groups?

No

Q14b. If data is available to other groups what is the access policy/mechanisms for access?
Q15. What data sharing policy is specified as a condition of use?

Data made publicly available after a specified time point

Q16a. Are tissues/samples/DNA available to other groups?

No

Q16b i) If yes, please describe below
Q16b. ii) In what form are tissues/samples/DNA supplied?
Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

No

Q17. Is information on biological characteristics available to other groups?

No

Types:
Case Control Studies

Member States:
Australia

Diseases:
Alzheimer's disease & other dementias, Parkinson's disease & PD-related disorders

Years:
2016

Database Categories:
N/A

Database Tags:
N/A